ANHUI ANKE BIOTECHNOLOGY (GROUP) CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.27 CNY | -2.82% |
|
-6.45% | -19.08% |
| Apr. 25 | Anhui Anke Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 28 | Anhui Anke Biotechnology Co., Ltd. Proposes Final Dividend for 2023 | CI |
| Sales 2024 * | 3.64B 501M | Sales 2025 * | 4.24B 583M | Capitalization | 13.83B 1.9B |
|---|---|---|---|---|---|
| Net income 2024 * | 990M 136M | Net income 2025 * | 1.17B 162M | EV / Sales 2024 * | 3.99 x |
| Net Debt 2024 * | 730M 100M | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 3.26 x |
| P/E ratio 2024 * |
14.4
x | P/E ratio 2025 * |
12.2
x | Employees | 2,986 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 59.85% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.82% | ||
| 1 week | -6.45% | ||
| Current month | -3.16% | ||
| 1 month | -9.91% | ||
| 3 months | -17.22% | ||
| 6 months | -20.48% | ||
| Current year | -19.08% |
1 week
8.25
8.70
1 month
8.259.39
Current year
7.5611.77
1 year
7.5611.77
3 years
7.3417.31
5 years
7.3419.27
10 years
2.9919.27
| Managers | Title | Age | Since |
|---|---|---|---|
Li Hua Song
CEO | Chief Executive Officer | 67 | 93-04-30 |
Xian Yu Du
CHM | Chairman | 54 | - |
Jian Ping Yao
PSD | President | 52 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hui Zhao
BRD | Director/Board Member | 50 | 07-04-08 |
Li Hua Song
CEO | Chief Executive Officer | 67 | 93-04-30 |
Li Ming Song
BRD | Director/Board Member | 62 | 03-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-03 | 8.27 | -2.82% | 9 098 861 |
| 24-07-03 | 8.51 | -1.05% | 7,290,712 |
| 24-07-02 | 8.6 | -0.12% | 7,819,328 |
| 24-07-01 | 8.61 | +0.82% | 10,264,920 |
| 24-06-28 | 8.54 | -0.81% | 10,899,880 |
End-of-day quote Shenzhen S.E., July 03, 2024
More quotes
Anhui Anke Biotechnology Group Co Ltd is a China-based company mainly engaged in the research and development, production and sales of genetic engineering drugs and biological detection reagents. The Company's products mainly include biological products, modern Chinese patent medicines, chemical synthetic drugs, and peptide drugs. The Company's subsidiary business covers the research and development, production and sales of modern Chinese patent medicines, chemical synthetic drugs, peptide drugs, forensic DNA testing, cell drugs and other products.
Sector
Pharmaceuticals
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
8.27
CNY
Average target price
19.54
CNY
Spread / Average Target
+136.28%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -19.08% | 1.96B | |
| +3.79% | 95.71B | |
| +5.66% | 41.64B | |
| -13.20% | 32.7B | |
| +79.53% | 28.65B | |
| -16.02% | 15.38B | |
| -8.17% | 12.97B | |
| -13.35% | 11.47B | |
| +160.91% | 9.92B | |
| -56.29% | 9.07B |
- Stock Market
- Equities
- 300009 Stock
